EANS-Adhoc: - The Marseille-Kliniken Group focuses on its core competency - nursing care - Revenues increased in the first three quarters of 2009/2010 by 6.3% to EUR 186.1 million - EBIT/IFRS rose to EUR 3.9 million compared to EUR 1.4 million in the p
-------------------------------------------------------------------------------- ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------------
quarterly report
10.05.2010
Berlin, 10 May 2010. The Marseille-Kliniken Group (Prime Standard, ISIN DE 0007783003, MKA) increased its operating sales by 6.3% to EUR 186.1 million (previous year: EUR 175.1 million) in the first nine months of the 2009/2010 financial year (1 July 2009 - 31 March 2010). EBITDAR/IFRS increased from EUR 43.1 million to EUR 47.1 million. EBIT/IFRS amounted to EUR 3.9 million compared to EUR 1.4 million in the previous year. Net profit before minority interests amounted to EUR -1.3 million in the period under review. This corresponds to an increase of EUR 1.8 million compared to EUR -3.1 million in the previous year. Earnings per share therefore rose to EUR -0.12 (previous year: EUR -0.25). Shareholders´ equity dropped from EUR 74.7 million to EUR 60.1 million and the equity ratio fell from 33.3% to 27.3% as a result. Financial debt decreased from EUR 68.7 million to EUR 61.1 million. Marseille-Kliniken Group evaluates these figures as a proof of constantly positive effects due to the intensive activities in sales and cost optimizing.
With 322 beds being added, the occupancy rate remained almost at the same high level as in the previous year. The 9,417 beds held by the Group accounted for an occupancy rate of 92.4% (previous year: 92.5%; 9,085 beds). As from the end of the period under review, the Marseille-Kliniken Group will no longer adjust selected profit figures in accordance with DVFA/SG (IFRS). This measure aims at increasing the transparency of the accounting measures.
The care division increased its capacity from 7,756 to 8,088 beds as of the balance sheet date, making it solely responsible for the Group's rise in capacity. Beds were added at the facilities in Bremerhaven, Oberhausen and Waldkirch. Segment revenues increased from EUR 134.6 million in the previous year to EUR 142.7 million, mainly due to higher sales from these three facilities. Earnings after taxes and before minority interests of EUR -1.0 million (previous year: EUR -2.1 million) were negatively affected by start-up losses for new facilities of EUR 5.7 million (previous year: EUR 5.4 million). The sale of a property in Bremerhaven amounting to EUR 1.6 million, on the other hand, had a positive effect. The occupancy rate at continually existing care facilities was 92.1% compared to 92.4% in the previous year.
Capacity of the rehabilitation division remained unchanged year-on-year at 1,329 beds. The division´s revenues rose from EUR 40.5 million in the previous year to EUR 43.3 million. Earnings after taxes and before minority interests increased from EUR -0.9 million to EUR -0.3 million. The segment´s occupancy rate rose from 92.7% to 94.3%.
In the fourth quarter of the current financial year, the Marseille-Kliniken Group disposed of all its rehabilitation clinics. The respective subsidiaries were deconsolidated as of 30 April 2010 and are therefore of no further relevance to future planning. Revenues generated by this sale are being used for developing and expanding the Group´s core division - care.
Marseille-Kliniken Group has introduced regional managers, who are to increase occupancy rates, and therefore revenues, in seven regions in order to improve its core competency nursing care. Special attention is being paid to those facilities with the largest potential for improvement. In order to increase profitability as well, various optimisation programmes have been implemented to reduce personnel costs and cost of materials without compromising the Group's high quality standards. As a consequence, the Marseille-Kliniken Group anticipates positive earnings in the current financial year.
For more detailed information please refer to the quarterly report, which is being published today on our website at www.marseille-kliniken.com.
End of ad hoc release
end of announcement euro adhoc --------------------------------------------------------------------------------
Further inquiry note:
Hillermann Consulting
Christian Hillermann
Investor Relations for Marseille-Kliniken AG
Poststraße 14/16
20354 Hamburg
Germany
Tel.: +49 (0)40 / 320 279-10
Fax: +49 (0)40 / 320 279-114
www.hillermann-consulting.de
;
Marseille-Kliniken AG
Dr. Ute Buchheim
Friedrich-Ebert-Str. 65
33330 Gütersloh
Germany
Tel.: +49 (0)5241 / 90 39-35
Fax: +49 (0)5241 / 90 39-39
www.marseille-kliniken.com
Branche: Pharmaceuticals
ISIN: DE0007783003
WKN: 778300
Index: CDAX, Classic All Share, Prime All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Stuttgart / free trade
Düsseldorf / free trade
Hamburg / regulated dealing
Original content of: Marseille-Kliniken AG, transmitted by news aktuell